Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer

NCT04191382 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04191382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04191382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
February 4, 2020
Completion date
May 28, 2021
Enrollment
105 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer